3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
7
Breast Neoplasms
5
Glioma
4
Glioblastoma
4
Neoplasms
3
Gliosarcoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Pleural Effusion
1
Pheochromocytoma
1
Interventions
3-Iodobenzylguanidine
8
anlotinib
4
Temozolomide
4
lutetium Lu 177 dotatate
3
Phenoxybenzamine
3
Everolimus
3
pegfilgrastim
2
cabozantinib
2
Granulocyte Colony-Stimulating Factor
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Adrenalectomy
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
vandetanib
1
temsirolimus
1
pentetreotide
1
penpulimab
1
pembrolizumab
1
olaparib
1
lenvatinib
1
lanreotide
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pheochromocytoma
×
vandetanib
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn